Profound Medical Corp T.PRN

Alternate Symbol(s): PROF

Technology Scientific & Technical Instruments

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

TSX:PRN - Post by User

Profound Medical Corp

Bullboard Posts

Comment by billy4325on Jan 08, 2019 3:24pm

68 Views

Post# 29202091

RE:Mackie ...

Not sure where you're getting this, but here's a link which provides some related info.

https://www.cantechletter.com/2019/01/profound-medical-is-a-buy-says-mackie-research-2/

Price target $1.10 (speculative buy).

MUGMODs wrote: After its preliminary quarterly revenue results, Mackie Research analyst Andr Uddin remains bullish on medical device company Profound Medical Corp (Profound Medical Stock Quote, Chart TSXV:PRN), which should be able to launch its real-time magnetic resonance imaging and ultrasound technology, the TULSA-PRO, in the United States by the second half of 2019. ***Fingers crossed that we have "smooth sailing" from here!

Bullboard Posts

A potential breakthrough in spinal cord and optic nerve injury treatment